Table 2. Risks of First Occurrence of Primary and Secondary Outcome Events During Extended Follow-up.

Outcome	No. (%) of participants		Unadjusted hazard ratio		Adjusted hazard ratio
	Start antiplatelet therapy (n = 268)	Avoid antiplatelet therapy (n = 268)	Estimate (95% CI)	P value	Estimate (95% CI)	P value
Recurrent symptomatic spontaneous intracerebral hemorrhage	22 (8.2)	25 (9.3)	0.87 (0.49-1.54)	.63	0.87 (0.49-1.55)	.64
Recurrent symptomatic spontaneous intracerebral hemorrhage or symptomatic stroke of uncertain subtype	23 (8.6)	28 (10.4)	0.81 (0.47-1.41)	.46	0.81 (0.47-1.41)	.46
Recurrent symptomatic spontaneous intracerebral hemorrhage or death of undetermined cause	25 (9.3)	33 (12.3)	0.76 (0.45-1.27)	.29	0.75 (0.45-1.27)	.29
All major hemorrhagic events (all types of symptomatic spontaneous or traumatic intracranial hemorrhage or symptomatic major extracranial hemorrhage)	32 (11.9)	30 (11.2)	1.07 (0.65-1.75)	.80	1.07 (0.65-1.76)	.79
All major occlusive vascular events (ischemic stroke, myocardial infarction, mesenteric ischemia, peripheral arterial occlusion, deep vein thrombosis, pulmonary embolism, or carotid/coronary/peripheral arterial revascularization procedures)	57 (21.3)	53 (19.8)	1.08 (0.74-1.56)	.70	1.09 (0.75-1.59)	.64
Major occlusive vascular events (as proposed in the trial protocol)	65 (24.3)	71 (26.5)	0.90 (0.64-1.26)	.53	0.90 (0.64-1.26)	.55
Major vascular events (as proposed in the trial protocol: nonfatal myocardial infarction, nonfatal stroke, or death from a vascular cause [including sudden death, pulmonary embolism, hemorrhage, and death from an unknown cause])	72 (26.8)	87 (32.5)	0.79 (0.58-1.08)	.16	0.79 (0.58-1.08)	.14